Literature DB >> 26987268

Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.

Liting Zhou1, Yanqing Song2, Jing Zhao3, Hongyan Qin1, Guoqiang Zhang1, Yan Zhou1, Xin'an Wu1.   

Abstract

CONTEXT: Drug-induced liver injury (DILI) is associated with altering expression of hepatobiliary membrane transporters. Monoammonium glycyrrhizin (MAG) is commonly used for hepatic protection and may have a correlation with the inhibition effect of multidrug resistance-associated protein 2 (Mrp2).
OBJECTIVE: This study evaluates the dynamic protective effect of MAG on rifampicin (RIF)- and isoniazid (INH)-induced hepatotoxicity in rats.
MATERIALS AND METHODS: Male Wistar rats were randomly divided into four groups of 15 rats. Liver injury was induced by co-treatment with RIF (60 mg/kg) and INH (60 mg/kg) by gavage administration; MAG was orally pretreated at the doses of 45 or 90 mg/kg 3 h before RIF and INH. Rats in each group were sacrificed at 7, 14, and 21 d time points after drug administration.
RESULTS: Liver function, histopathological analysis, and oxidative stress factors were significantly altered in each group. The expression of Mrp2 was significantly increased 230, 760, and 990% at 7, 14, and 21 time points, respectively, in RIF- and INH-treated rats. Compared with the RIF and INH groups, Mrp2 was reduced and Ntcp was significantly elevated by 180, 140, and 160% in the MAG high-dose group at the three time points, respectively. The immunoreaction intensity of Oatp1a4 was increased 170, 190, and 370% in the MAG low-dose group and 160, 290, and 420% in the MAG high-dose group at the three time points, respectively, compared with the RIF and INH groups. DISCUSSION AND
CONCLUSION: These results indicated that MAG has a protective effects against RIF- and INH-induced hepatotoxicity. The underlying mechanism may have correlation with its effect on regulating the expression of hepatobiliary membrane transporters.

Entities:  

Keywords:  Anti-tuberculosis agent; glycyrrhizin acid; hepatoprotective; liver injury

Mesh:

Substances:

Year:  2016        PMID: 26987268     DOI: 10.3109/13880209.2015.1070878

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  5 in total

1.  Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation.

Authors:  Tingting Yan; Hong Wang; Lijuan Cao; Qiong Wang; Shogo Takahashi; Tomoki Yagai; Guolin Li; Kristopher W Krausz; Guangji Wang; Frank J Gonzalez; Haiping Hao
Journal:  Drug Metab Dispos       Date:  2018-06-29       Impact factor: 3.922

Review 2.  Molecular mechanism and research progress on pharmacology of traditional Chinese medicine in liver injury.

Authors:  Hong Yang Zhang; Hong Ling Wang; Guo Yue Zhong; Ji Xiao Zhu
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

Review 3.  Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs.

Authors:  Yongfeng Zhou; Junnan Wang; Dingkun Zhang; Jiaxin Liu; Qinghua Wu; Jiang Chen; Peng Tan; Boyu Xing; Yanzhong Han; Ping Zhang; Xiaohe Xiao; Jin Pei
Journal:  Chin Med       Date:  2021-12-11       Impact factor: 5.455

4.  Cardioprotective Effect of Monoammonium Glycyrrhizinate Injection Against Myocardial Ischemic Injury in vivo and in vitro: Involvement of Inhibiting Oxidative Stress and Regulating Ca2+ Homeostasis by L-Type Calcium Channels.

Authors:  Zhifeng Zhao; Miaomiao Liu; Yuanyuan Zhang; Yingran Liang; Donglai Ma; Hongfang Wang; Zhihong Ma; Shengjiang Guan; Zhonglin Wu; Xi Chu; Yue Lin; Li Chu
Journal:  Drug Des Devel Ther       Date:  2020-01-23       Impact factor: 4.162

5.  Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19.

Authors:  Ken Sato; Yuichi Yamazaki; Toshio Uraoka
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.